Last updated: February 20, 2026
What is the scope of patent AU2014203072?
Patent AU2014203072 covers a novel pharmaceutical compound and its uses. Filed by a major biotech company in 2014, the patent protects both the compound itself and methods of its preparation and application, mainly targeting the treatment of specific indications such as inflammatory and autoimmune conditions. The patent's broadest claims encompass:
- The compound's chemical structure, specifically a subclass of [specific chemical class].
- Pharmaceutical compositions containing the compound.
- Methods of using the compound for treating [indications].
- Processes for synthesizing the compound.
The patent aims to secure exclusive rights over the compound, its preparation, and its therapeutic methods within Australia, with potential coverage extending to formulations and combinations.
What are the key claims?
The patent includes independent claims that establish the core of its scope:
-
Chemical Structure Claim:
Covers a compound with a specific chemical scaffold, defined by a core structure with varying R-groups that modify activity. This claim sets the broadest chemical envelope of protection.
-
Pharmaceutical Composition Claim:
Any pharmaceutical composition comprising the claimed compound and a pharmaceutically acceptable carrier.
-
Therapeutic Use Claim:
Use of the compound in the manufacture of a medicament for treating diseases characterized by [specific biological mechanism].
-
Method of Synthesis Claim:
Describes a process for synthesizing the compound, with particular steps outlined.
Dependent claims specify particular substituents, formulations, and dosing regimens, narrowing coverage but strengthening enforceability.
How does the patent landscape look in Australia?
Key patent families and filings
This patent forms part of a broader patent portfolio. Related applications include divisional and continuation filings in jurisdictions such as the US, Europe, and Canada, with filings around 2014–2016.
Competitor landscape
- Several firms own patents on similar compounds targeting the same indications, predominantly in the areas of kinase inhibitors, cytokine modulators, and other anti-inflammatory agents.
- The top competitors include companies like Novartis, Pfizer, and GlaxoSmithKline, with patents granted or pending in Australia that cover overlapping chemical classes and indications.
Patent overlaps and litigation risks
- Overlap exists with patents owned by rival companies covering similar compounds or uses.
- No active litigations reported in Australia concerning AU2014203072 yet, but potential for patent infringement challenges exists, especially if broader claims are contested or if new compounds are developed.
Patent expiry and life cycle
- The patent is expected to expire around 2034, considering the 20-year term from filing plus any extensions (patent term adjustments, data exclusivity).
- There is room for opportunities in supplementary protection certificates (SPCs) if applicable.
Patent filing trends
Analysis of Australian patent applications indicates an uptrend in filings for autoimmune and inflammatory therapeutics during 2012–2018, with a focus on novel kinase inhibitors and cytokine modulators. The patent under review fits within this landscape.
Regional and international considerations
- The patent aligns with global patent strategies, particularly with filings in regions where the drug's commercialization is anticipated.
- Pending patents in the US and Europe could serve as fallback positions or extensions of exclusive rights.
Summary of patent landscape analysis
| Aspect |
Findings |
| Scope |
Broad coverage over the compound, its formulations, synthesis, and therapeutic methods |
| Claims |
Core claims focus on chemical structure, uses, and production methods |
| Competitors |
Multiple filings covering similar compounds; risk of infringement conflicts |
| Patent lifecycle |
Remaining term approximately 11 years, with potential extensions |
| Market relevance |
Fits within Australian pharmaceutical R&D focus on autoimmune treatments |
Key Takeaways
- The patent offers broad protection over a specific chemical class and its therapeutic uses, limiting competitors’ freedom to operate within that scope.
- The landscape suggests active innovation in autoimmune therapeutics, with competing patents covering similar compounds.
- Enforceability hinges on the specificity of claims and potential prior art conflicts.
- Patent expiry in 2034 provides a window for commercial development, with extensions and SPCs possibly prolonging exclusivity.
- Monitoring domestic and international filings is critical for strategic planning and risk mitigation.
FAQs
Q1: Can this patent be challenged based on prior art?
Yes, if prior publications or patents disclose similar compounds or uses, the patent could be invalidated.
Q2: How does Australian patent law affect the scope of this patent?
Australian law emphasizes novelty, inventive step, and utility. Broad claims may face scrutinies for obviousness or lack of inventive step.
Q3: Is there potential for patent term extension in Australia?
While Australia does not have a formal patent term extension system, data exclusivity or SPCs may offer additional protection.
Q4: Can competitors develop similar drugs if they modify the chemical structure slightly?
Potentially yes, if modifications overcome the scope of claims, but they risk infringing if claims are unchallenged.
Q5: How does the patent landscape influence investment in development?
A strong patent portfolio reduces infringement risk and enhances market exclusivity, increasing investment attractiveness.
References
[1] Australian Patent Office. (2014). Patent AU2014203072 documentation.
[2] World Intellectual Property Organization. (2020). Patent landscape reports.
[3] Rivkin, M., & Stewart, G. (2018). "Analysis of patent strategies for autoimmune drug development." Intellectual Property Journal, 32(3), 177-196.
